Search clinical trials for: VEN (Venetoclax)

Total 2528 results

Dalian Medical University

Not yet recruiting

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Mantle Cell Lymphoma

China
Poitiers University Hospital

Recruiting

Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Waldenstrom's Macroglobulinaemia Refractory

France
National Taiwan University Hospital

Recruiting

Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Taiwan
National Taiwan University Hospital

Recruiting

Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan
Tanta University

Unknown

Pre-operative Ultrasonographic Evaluation of the Internal Jugular Vein Collapsibility Index and Inferior Vena Cava Collapsibility Index to Predict Post Spinal Hypotension in Pregnant Women Undergoing Caesarean Section

Cesarean Section
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | NPM1 Mutation

Italy
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT

Acute Myeloid Leukemia

Italy
The First Affiliated Hospital of Soochow University

Recruiting

Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML (VHA)

Acute Myeloid Leukemia

China
Thomas Ernst, PD Dr. med.
AbbVie; Ludwig-Maximilians - University of Munich

Recruiting

Venetoclax After TKI to Target Persisting Stem Cells in CML (VARIANT)

Chronic Myeloid Leukemia

Germany
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Recruiting

A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Chronic Lymphocytic Leukemia | Refractory Leukemia | Relapse Leukemia

Italy
French Innovative Leukemia Organisation

Recruiting

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Chronic Lymphoid Leukemia

France
University of Alabama at Birmingham

Completed

Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Children's Hospital Medical Center, Cincinnati

Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Lymphoma | Follicular Lymphoma | Leukemia | B Cell Lymphoma | Hodgkin Lymphoma | Burkitt Lymphoma | AML | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | T-cell Lymphoma | Peripheral T Cell Lymphoma and other conditions

United States
The First Affiliated Hospital of Soochow University

Recruiting

Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

Acute Myeloid Leukemia, Adult

China
University of Colorado, Denver

Active, not recruiting

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Acute Myeloid Leukemia

United States
Pfizer

Withdrawn

Acute Myeloid Leukemia Real World Treatment Patterns

Leukemia, Myeloid, Acute
Swiss Group for Clinical Cancer Research

Terminated

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Non-Hodgkin Lymphoma

Switzerland
AbbVie
Infinity Pharmaceuticals, Inc.

Withdrawn

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma

United States
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Hematologic Malignancy | Stem Cell Transplant Complications

China
AbbVie
Genentech, Inc.

Completed

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia
Rigshospitalet, Denmark
Vestre Viken Hospital Trust; Karolinska University Hospital; Helsinki University... and other collaborators

Recruiting

Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling (LD-VenEx)

Acute Myeloid Leukemia

Denmark
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia (V-FIRST)

Acute Myeloid Leukemia

Italy
University of Leipzig
AbbVie; University Hospital Leipzig, Hematology Diagnostics Laboratory; University...

Recruiting

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

Acute Myeloid Leukemia (AML)

Germany
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Recruiting | T-cell Acute Lymphoblastic Leukemia

China
Stichting Hemato-Oncologie voor Volwassenen Nederland
German CLL Study Group; Nordic CLL Study Group

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER)

CLL/SLL

Netherlands, Denmark, Belgium, Germany
Dana-Farber Cancer Institute
AbbVie

Completed

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (DHODH)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United Kingdom, France, Korea, Republic of, Spain
The First Affiliated Hospital of Soochow University
The Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaborators

Recruiting

Venetoclax Based Regimen for R/R T-ALL

Acute T-Lymphocytic Leukemia

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax (ENABLE)

Acute Myeloid Leukemia

Italy
Genfleet Therapeutics (Shanghai) Inc.
Sellas Life Sciences Group

Recruiting

A Study of GFH009 in Patients With Hematologic Malignancies

Hematologic Malignancies

China, United States
Novartis Pharmaceuticals

Completed

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
AbbVie
Genentech, Inc.

Completed

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Australia
AbbVie

Recruiting

A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Healthy Volunteers

United States
Hannover Medical School

Recruiting

Venetoclax Registry (VENreg)

Acute Myeloid Leukemia

Germany
Sanjay Mohan
AbbVie; Karyopharm Therapeutics Inc

Active, not recruiting

Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States
Dana-Farber Cancer Institute
AbbVie

Active, not recruiting

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Completed

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

AML | MDS

United States
Curis, Inc.
The Leukemia and Lymphoma Society

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditions

United States
Aprea Therapeutics

Terminated

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (R/R)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
Delta-Fly Pharma, Inc.

Not yet recruiting

Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Acute Myeloid Leukemia

Italy, Poland
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Large B-cell, Diffuse

United States, Canada, Germany
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (VIS)

Chronic Lymphocytic Leukemia | High Risk CLL

Italy
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital; Dongguan People's Hospital; Huizhou Municipal Central... and other collaborators

Recruiting

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Leukemia, Myeloid, Acute | Refractory Leukemia | Relapsed Adult AML

China
ALX Oncology Inc.

Active, not recruiting

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Acute Myeloid Leukemia | AML, Adult

United States
AbbVie
Celgene; Genentech, Inc.

Completed

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Germany
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (Captivate)

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Italy, New Zealand, Poland, Spain
Novartis Pharmaceuticals

Active, not recruiting

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Acute Myeloid Leukemia

Italy, Hong Kong, Israel, Hungary, Turkey, Malaysia, United States
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan

Search clinical trials for: VEN (Venetoclax)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations